Background The development of skin rashes is the most common adverse event observed in
cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such …

Aim The aim of this study was to investigate if biomarkers of individual drug metabolism,
respectively, the erlotinib/O-desmethyl-erlotinib metabolic ratio, may be a predictive factor for …

Background Skin toxicity is a common adverse effect of erlotinib and other anti-epidermal
growth factor receptor (EGFR) agents. The aim of the study was to explore the relationship …

Although drug distribution in tumor tissues has a significant impact on efficacy, conventional
pharmacokinetic analysis has some limitations with regard to its ability to provide a …

Combination therapy of erlotinib plus bevacizumab improves progression-free survival of
patients with epidermal growth factor receptor–mutated (EGFR-mutated) advanced non …

Erlotinib is a necessary anticancer treatment for non-small cell lung cancer (NSCLC)
patients yet it causes severe side effects such as skin rash. In this study, researchers …

The review concluded that there was a significant risk of all-grade and high-grade rash
associated with erlotinib use in cancer patients, which may be modified by chemotherapy …

18538 Background: Erlotinib is an oral epidermal growth factor receptor (EGFR) targeted
therapy. It is approved for therapy in NSCLC pts after failure of at least one prior …

A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor
(EGFR) inhibitor erlotinib in combination with gemcitabine was especially efficient in a …

Erlotinib is a reversible epidermal growth factor receptor tyrosine kinase inhibitor used to
treat advanced non–small cell lung carcinoma patients who have shown progression on at …